Search HDBuzz

A spoonful of branaplam helps the huntingtin go down

Branaplam was originally designed to treat spinal muscular atrophy, but a new paper outlines how it could hold promise for treating Huntington’s. This oral drug lowers huntingtin protein and will now be tested in a study called VIBRANT-HD.

Dr Rachel Harding | March 16, 2022

Huntington’s disease therapeutics conference 2022 - Day 1

Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2022

Dr Rachel Harding, Dr Leora Fox, Dr Sarah Hernandez, and Joel Stanton | June 20, 2022

Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.

Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntington’s disease observational trials to model progression of the disease. They hope their findings will help improve clinical trial design.

Dr Rachel Harding | June 21, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah Hernandez | August 31, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Sarah Hernandez and Dr Rachel Harding | September 02, 2022

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.

Dr Jeff Carroll and Dr Leora Fox | September 30, 2022

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.

Dr Rachel Harding | December 09, 2022

PROOF-HD study of pridopidine ends with negative result

The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease

Professor Ed Wild | April 25, 2023

Huntington’s disease therapeutics conference 2023 - Day 1

Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara Maiuri | April 26, 2023

Huntington’s disease therapeutics conference 2023 - Day 2

Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara Maiuri | May 04, 2023

You can also read About HDBuzz for information on HDBuzz or try your search on a search engine.